A first-in-human, phase 1 study of the NEDD8 activating enzyme E1 inhibitor TAS4464 in patients with advanced solid tumors

Background This open-label, phase 1 study investigated TAS4464, a potent NEDD8-activating enzyme inhibitor, in patients with advanced/metastatic solid tumors (JapicCTI-173,488; registered 13/01/2017). The primary objective was dose-limiting toxicities (DLTs). Maximum-tolerated dose (MTD) was investi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Invest New Drugs
Autors principals: Yamamoto, Noboru, Shimizu, Toshio, Yonemori, Kan, Kitano, Shigehisa, Kondo, Shunsuke, Iwasa, Satoru, Koyama, Takafumi, Sudo, Kazuki, Sato, Jun, Tamura, Kenji, Tomomatsu, Junichi, Ono, Makiko, Fukuda, Naoki, Takahashi, Shunji
Format: Artigo
Idioma:Inglês
Publicat: Springer US 2021
Matèries:
Phase I Studies
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8279981/
https://ncbi.nlm.nih.gov/pubmed/33560503
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-020-01055-5
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars